Clinical Trial Update: Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating INM004 for prevention of hemolytic uremic syndrome in STEC-positive pediatric patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bloody Diarrhea
• Hemolytic Uremic Syndrome
• Kidney Disease
• Shiga Toxin-producing Coli Infection

Drugs mentioned

• INM004

Snippet

Sponsor: Inmunova S.A. | Conditions: Bloody Diarrhea, STEC, Unspecified | Phase 2, Phase 3 | Status: TERMINATED